JP2020520718A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020520718A5 JP2020520718A5 JP2019564141A JP2019564141A JP2020520718A5 JP 2020520718 A5 JP2020520718 A5 JP 2020520718A5 JP 2019564141 A JP2019564141 A JP 2019564141A JP 2019564141 A JP2019564141 A JP 2019564141A JP 2020520718 A5 JP2020520718 A5 JP 2020520718A5
- Authority
- JP
- Japan
- Prior art keywords
- region
- acoustic response
- target bbb
- surrounding
- response
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000008499 blood brain barrier function Effects 0.000 claims description 61
- 210000001218 blood-brain barrier Anatomy 0.000 claims description 61
- 238000000034 method Methods 0.000 claims description 29
- 230000001186 cumulative effect Effects 0.000 claims description 18
- 238000003384 imaging method Methods 0.000 claims description 10
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 229940124597 therapeutic agent Drugs 0.000 claims description 6
- 238000005259 measurement Methods 0.000 claims description 5
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 claims description 4
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 claims description 4
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 4
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 claims description 4
- 229960001101 ifosfamide Drugs 0.000 claims description 4
- 229960002247 lomustine Drugs 0.000 claims description 4
- 230000002093 peripheral effect Effects 0.000 claims description 4
- -1 temozolomid Chemical compound 0.000 claims description 4
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims description 4
- 229960004528 vincristine Drugs 0.000 claims description 4
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims description 4
- 238000001914 filtration Methods 0.000 claims description 3
- VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 claims description 2
- JHUJMHKRHQPBRG-UHFFFAOYSA-N 4-Hydroxyifosfamide Chemical compound OC1CCOP(=O)(NCCCl)N1CCCl JHUJMHKRHQPBRG-UHFFFAOYSA-N 0.000 claims description 2
- FJHBVJOVLFPMQE-QFIPXVFZSA-N 7-Ethyl-10-Hydroxy-Camptothecin Chemical compound C1=C(O)C=C2C(CC)=C(CN3C(C4=C([C@@](C(=O)OC4)(O)CC)C=C33)=O)C3=NC2=C1 FJHBVJOVLFPMQE-QFIPXVFZSA-N 0.000 claims description 2
- 108010006654 Bleomycin Proteins 0.000 claims description 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 2
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 claims description 2
- 102100021906 Cyclin-O Human genes 0.000 claims description 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims description 2
- 101000897441 Homo sapiens Cyclin-O Proteins 0.000 claims description 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 2
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims description 2
- 229930012538 Paclitaxel Natural products 0.000 claims description 2
- FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 claims description 2
- 150000008209 arabinosides Chemical class 0.000 claims description 2
- DRTQHJPVMGBUCF-CCXZUQQUSA-N arauridine Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-CCXZUQQUSA-N 0.000 claims description 2
- 229960001561 bleomycin Drugs 0.000 claims description 2
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 claims description 2
- 229960002092 busulfan Drugs 0.000 claims description 2
- 229960004562 carboplatin Drugs 0.000 claims description 2
- 190000008236 carboplatin Chemical compound 0.000 claims description 2
- 229960005243 carmustine Drugs 0.000 claims description 2
- 229960004316 cisplatin Drugs 0.000 claims description 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 2
- 229960000684 cytarabine Drugs 0.000 claims description 2
- 238000001514 detection method Methods 0.000 claims description 2
- 229960003668 docetaxel Drugs 0.000 claims description 2
- 229960004679 doxorubicin Drugs 0.000 claims description 2
- 229960002949 fluorouracil Drugs 0.000 claims description 2
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims description 2
- 229960004768 irinotecan Drugs 0.000 claims description 2
- 229960000485 methotrexate Drugs 0.000 claims description 2
- 229960001420 nimustine Drugs 0.000 claims description 2
- VFEDRRNHLBGPNN-UHFFFAOYSA-N nimustine Chemical compound CC1=NC=C(CNC(=O)N(CCCl)N=O)C(N)=N1 VFEDRRNHLBGPNN-UHFFFAOYSA-N 0.000 claims description 2
- KPMKNHGAPDCYLP-UHFFFAOYSA-N nimustine hydrochloride Chemical compound Cl.CC1=NC=C(CNC(=O)N(CCCl)N=O)C(N)=N1 KPMKNHGAPDCYLP-UHFFFAOYSA-N 0.000 claims description 2
- 229960001592 paclitaxel Drugs 0.000 claims description 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 2
- 229960001196 thiotepa Drugs 0.000 claims description 2
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 claims description 2
- 230000003213 activating effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000001700 effect on tissue Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762510023P | 2017-05-23 | 2017-05-23 | |
| US62/510,023 | 2017-05-23 | ||
| PCT/IB2018/000774 WO2018215839A2 (en) | 2017-05-23 | 2018-05-22 | Systems and methods for selective, targeted opening of the blood-brain barrier |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020520718A JP2020520718A (ja) | 2020-07-16 |
| JP2020520718A5 true JP2020520718A5 (enExample) | 2021-03-11 |
| JP7111744B2 JP7111744B2 (ja) | 2022-08-02 |
Family
ID=63840879
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019564141A Active JP7111744B2 (ja) | 2017-05-23 | 2018-05-22 | 血液脳関門の選択的標的開放のためのシステムおよび方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US11918832B2 (enExample) |
| EP (1) | EP3630262A2 (enExample) |
| JP (1) | JP7111744B2 (enExample) |
| CN (1) | CN110662575B (enExample) |
| WO (1) | WO2018215839A2 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN120324803A (zh) | 2018-11-28 | 2025-07-18 | 希斯托索尼克斯公司 | 组织摧毁术系统及方法 |
| US11879973B2 (en) * | 2018-12-18 | 2024-01-23 | Insightec, Ltd. | Echo-based focusing correction |
| WO2020193667A2 (en) * | 2019-03-25 | 2020-10-01 | Creaholic S.A. | Treatment parameters for acoustic wave stimulation |
| WO2020206281A1 (en) * | 2019-04-04 | 2020-10-08 | Northwestern University | Improved delivery of drug therapy to the cns by ultrasound-based opening of the blood-brain barrier |
| US11730452B2 (en) * | 2019-04-09 | 2023-08-22 | Insightec Ltd. | Systems and methods for regulating microbubbles in ultrasound procedures |
| WO2021069971A1 (en) | 2019-10-11 | 2021-04-15 | Insightec, Ltd. | Pre-treatment tissue sensitization for focused ultrasound procedures |
| EP4096782A4 (en) | 2020-01-28 | 2024-02-14 | The Regents Of The University Of Michigan | SYSTEMS AND METHODS FOR HISTOTRIPSIA IMMUNOSENSITIZATION |
| WO2021262355A1 (en) * | 2020-06-22 | 2021-12-30 | Medtronic Navigation, Inc. | Protecting non-target tissue during ablation procedures and related systems and methods |
| EP3957299A1 (en) * | 2020-08-17 | 2022-02-23 | ETH Zurich | Localized delivery of diagnostic or therapeutic agents using focused ultrasound |
| AU2021332372A1 (en) | 2020-08-27 | 2023-03-16 | The Regents Of The University Of Michigan | Ultrasound transducer with transmit-receive capability for histotripsy |
| US12366583B2 (en) | 2022-10-24 | 2025-07-22 | West Virginia University Board of Governors on behalf of West Virginia University | Methods of improving neurodegenerative disorders by targeted delivery of therapeutic agents |
| EP4608504A1 (en) | 2022-10-28 | 2025-09-03 | Histosonics, Inc. | Histotripsy systems and methods |
| WO2024201441A1 (en) | 2023-03-29 | 2024-10-03 | Insightec Ltd. | Monitoring and control of histotripsy procedures |
| AU2024257180A1 (en) | 2023-04-20 | 2025-09-18 | Histosonics, Inc. | Histotripsy systems and associated methods including user interfaces and workflows for treatment planning and therapy |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070016039A1 (en) | 2005-06-21 | 2007-01-18 | Insightec-Image Guided Treatment Ltd. | Controlled, non-linear focused ultrasound treatment |
| US20070083120A1 (en) | 2005-09-22 | 2007-04-12 | Cain Charles A | Pulsed cavitational ultrasound therapy |
| US8057408B2 (en) | 2005-09-22 | 2011-11-15 | The Regents Of The University Of Michigan | Pulsed cavitational ultrasound therapy |
| EP2440292A1 (en) * | 2009-06-10 | 2012-04-18 | Insightec Ltd. | Acoustic-feedback power control during focused ultrasound delivery |
| CN101698121B (zh) * | 2009-10-23 | 2011-06-22 | 西安交通大学 | 促进药物透过血脑屏障的适型超声系统 |
| US20130079682A1 (en) * | 2011-09-25 | 2013-03-28 | David J. Mischelevich | Ultrasound-neuromodulation techniques for control of permeability of the blood-brain barrier |
| US10322178B2 (en) * | 2013-08-09 | 2019-06-18 | The Trustees Of Columbia University In The City Of New York | Systems and methods for targeted drug delivery |
| US9956388B2 (en) | 2014-06-04 | 2018-05-01 | Sonescence, Inc. | Systems and methods for therapeutic agent delivery |
| CN104146730A (zh) * | 2014-08-18 | 2014-11-19 | 中国人民解放军第三军医大学第二附属医院 | 医用诊断超声波激励微泡调控双侧血脑屏障通透性的用途 |
| JP6692887B2 (ja) * | 2015-03-27 | 2020-05-13 | プロファウンド メディカル インク | ターゲットボリュームのセットをソニケーション（超音波分解）するための医療機器 |
| US10076652B2 (en) * | 2015-08-10 | 2018-09-18 | Chang Gung University | Method for ultrasound-mediated delivery system to monitor molecular penetration |
-
2018
- 2018-05-22 WO PCT/IB2018/000774 patent/WO2018215839A2/en not_active Ceased
- 2018-05-22 US US16/607,509 patent/US11918832B2/en active Active
- 2018-05-22 EP EP18786026.7A patent/EP3630262A2/en active Pending
- 2018-05-22 CN CN201880034342.1A patent/CN110662575B/zh active Active
- 2018-05-22 JP JP2019564141A patent/JP7111744B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020520718A5 (enExample) | ||
| JP2020525167A5 (enExample) | ||
| JP7111744B2 (ja) | 血液脳関門の選択的標的開放のためのシステムおよび方法 | |
| O’Reilly et al. | Three-dimensional transcranial ultrasound imaging of microbubble clouds using a sparse hemispherical array | |
| EP3645116B1 (en) | Cavitation-enhanced targeted drug delivery and dosing | |
| JP2020525168A5 (enExample) | ||
| JP2020525169A5 (enExample) | ||
| JP2016518939A (ja) | 電気的刺激によって標的臓器の動脈の血流を減少させるシステム | |
| Chen et al. | Harmonic motion imaging for abdominal tumor detection and high-intensity focused ultrasound ablation monitoring: an in vivo feasibility study in a transgenic mouse model of pancreatic cancer | |
| JP6974308B2 (ja) | 脳の膨張と移動の少なくとも一方の亢進を検出する装置および方法 | |
| JP2005532097A5 (enExample) | ||
| JP4279328B2 (ja) | 超音波撮像システム | |
| US20100241001A1 (en) | Ultrasound Methods, Systems and Computer Program Products for Imaging Fluids | |
| Keller et al. | Cavitation therapy monitoring of commercial microbubbles with a clinical scanner | |
| Liu et al. | Design and implementation of a transmit/receive ultrasound phased array for brain applications | |
| Ellens et al. | Preclinical MRI-guided focused ultrasound: a review of systems and current practices | |
| Liu et al. | Cardiac MR elastography of the mouse: Initial results | |
| US11207053B2 (en) | Blood volume assessment using high frequency ultrasound | |
| JP2009285461A (ja) | 血管外遊出を検出する超音波システム及び方法 | |
| Anhalt et al. | Patterns of changes of tumour temperatures during clinical hyperthermia: implications for treatment planning, evaluation and control | |
| CN103083087B (zh) | 控制单元以及具有控制单元的医学检查装置 | |
| JP2006325746A (ja) | 超音波診断装置 | |
| Coiado et al. | Ultrasound-induced heart rate decrease: role of the vagus nerve | |
| Xu et al. | Real-time 3-dimensional contrast-enhanced ultrasound in detecting hemorrhage of blunt renal trauma | |
| Landry et al. | Ultrasound imaging guided precision histotripsy: Effects of pulse settings on ablation properties in rat brain |